Viracta Therapeutics, Inc.

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

Kronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp